U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H27N7O3S.ClH
Molecular Weight 481.999
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CERDULATINIB HYDROCHLORIDE

SMILES

Cl.CCS(=O)(=O)N1CCN(CC1)C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2

InChI

InChIKey=IYULGYKOHUAYCG-UHFFFAOYSA-N
InChI=1S/C20H27N7O3S.ClH/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14;/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H27N7O3S
Molecular Weight 445.538
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25253883

Cerdulatinib is an oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies – the B-cell receptor pathway via Syk and key cytokine receptors via JAK Being developed to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. Cerdulatinib is in Phase 2 study evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies.

Approval Year

TargetsConditions
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Rat: in a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg p.o.) significantly improves inflammatory infiltrate within the synovium and the integrity of the articular cartilage.
Route of Administration: Oral
In biochemical assays, cerdulatinib demonstrated inhibitory activity against 24 kinases with IC50’s < 200 nM. Cerdulatinib demonstrated sensitivity to cerdulatinib with IC50 at or below ~2 uM. ABC cell lines with relatively higher total and phosphorylated STAT3 displayed good sensitivity to the drug with IC50 ranging from 0.29 to 1.80 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 14:51:21 UTC 2023
Edited
by admin
on Sat Dec 16 14:51:21 UTC 2023
Record UNII
L1KRM66Y4X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CERDULATINIB HYDROCHLORIDE
Common Name English
5-PYRIMIDINECARBOXAMIDE, 4-(CYCLOPROPYLAMINO)-2-((4-(4-(ETHYLSULFONYL)-1-PIPERAZINYL)PHENYL)AMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
RVT-502 HYDROCHLORIDE
Code English
PRT062070
Code English
Code System Code Type Description
CAS
1369761-01-2
Created by admin on Sat Dec 16 14:51:21 UTC 2023 , Edited by admin on Sat Dec 16 14:51:21 UTC 2023
PRIMARY
PUBCHEM
56960607
Created by admin on Sat Dec 16 14:51:21 UTC 2023 , Edited by admin on Sat Dec 16 14:51:21 UTC 2023
PRIMARY
FDA UNII
L1KRM66Y4X
Created by admin on Sat Dec 16 14:51:21 UTC 2023 , Edited by admin on Sat Dec 16 14:51:21 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY